Annex A02 – High-Level Summary of Statistical Analysis Plan (SAP)

Study Title: Evergreen Registry – Post-Market Clinical Follow-up of the EvroSure Everolimus Drug Eluting CoCr Coronary Stent System

8th December 2022

1. Analysis Populations

- **Intention-to-Treat (ITT):** All patients enrolled, analyzed according to initial treatment assignment, regardless of protocol deviations.
- **Per-Protocol (PP):** Patients completing follow-up without major protocol deviations, used for sensitivity analyses.
- **Safety Population:** All patients who received at least one EvroSure stent implant, analyzed for adverse events.

2. Time-to-Event Analysis Methods

- **Kaplan-Meier survival curves** will be used to estimate cumulative incidence of stent thrombosis, MACE, TLR, and TVR.
- **Log-rank tests** may be applied for subgroup comparisons (e.g., small vessels, long lesions, diabetics).
- **Confidence intervals (95%)** will be reported for event-free survival estimates.

3. Handling of Missing Data

- **Primary approach:** Multiple imputation for incomplete follow-up data.
- **Sensitivity analyses:** Conducted to assess robustness of results under different missing data assumptions.
- **Lost-to-follow-up rates** will be documented and reported annually.

4. Interim Analysis Plan

- **Annual interim analyses** integrated into the Periodic Safety Update Report (PSUR).
- **Endpoints assessed:** MACE, stent thrombosis, TLR, TVR, and adverse events.
- **Final analysis:** Conducted at 5 years, with cumulative outcomes benchmarked against published second-generation DES trials (TWENTE, COMPARE, BIOSCIENCE, BIOFLOW V, ISAR-TEST 4).

- **Trigger criteria:** If interim results exceed predefined thresholds (e.g., stent thrombosis >0.5%, MACE >5%), corrective actions will be initiated (CER update, PMS signal investigation, RMF update).

5. Reporting

- Interim results reported annually to the Notified Body via PSUR.
- Final PMCF report submitted at 5 years, including full statistical analysis and subgroup outcomes.